Survival Is Poorer in Patients With Secondary Core-binding Factor Acute Myelogenous Leukemia Compared With De Novo Core-binding Factor Leukemia

被引：69

作者：

Borthakur, Gautam ^{[1
]}

Lin, E. ^{[2
]}

Jain, Nitin ^{[1
]}

Estey, Elihu E. ^{[3
]}

Cortes, Jorge E. ^{[1
]}

O'Brien, Susan ^{[1
]}

Faderl, Stefan ^{[1
]}

Ravandi, Farhad ^{[1
]}

Pierce, Sherry ^{[1
]}

Kantarjian, Hagop ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Quantitat Sci Div, Houston, TX 77030 USA

[3] Univ Washington, Dept Med, Div Hematol, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA

来源：

CANCER | 2009年 / 115卷 / 14期

关键词：

therapy-related; core-binding factor; acute myelogenous leukemia; overall survival; event-free survival; matched analysis; ACUTE MYELOID-LEUKEMIA; INTERNATIONAL WORKSHOP; THERAPY; INV(16); FUSION; REARRANGEMENTS; TRANSCRIPT; RELAPSE; CHAIN;

D O I：

10.1002/cncr.24367

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BACKGROUND: Therapy related secondary acute myelogenous leukemia (AML) was commonly associated with prior exposure to alkylating agents or topoisomerase inhibitor. The long-term outcome of such patients with secondary AML was found to be worse than that of patients with de novo AML. Earlier reports suggested similar outcomes for patients with de novo and secondary AML associated with core-binding factor (CBF) abnormalities. METHODS: A total of 188 patients with CBF AML were analyzed. The frequency of secondary CBF AML was 9%. RESULTS: Patients with secondary CBF AML were found to have significantly worse overall (OS) and event-free survival (EFS) compared with patients with de novo CBF AML. Secondary CBF AML status appeared to have only marginal significance in multivariate analysis. CONCLUSIONS: Matched analysis (by age, Eastern Cooperative Oncology Group performance status, and additional cytogenetic abnormality) indicated worse OS and EFS in patients with secondary CBF AML. Cancer 2009;115:3217-21. (C) 2009 American Cancer Society.

引用

页码：3217 / 3221

页数：5

共 17 条

[1] Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: Report from an international workshop [J].

Andersen, MK ;

Larson, RA ;

Mauritzson, N ;

Schnittger, S ;

Jhanwar, SC ;

Pedersen-Bjergaard, J .

GENES CHROMOSOMES & CANCER, 2002, 33 (04) :395-400

[2] The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations [J].

Appelbaum, Frederick R. ;

Kopecky, Kenneth J. ;

Tallman, Martin S. ;

Slovak, Marilyn L. ;

Gundacker, Holly M. ;

Kim, Haesook T. ;

Dewald, Gordon W. ;

Kantarjian, Hagop M. ;

Pierce, Sherry R. ;

Estey, Elihu H. .

BRITISH JOURNAL OF HAEMATOLOGY, 2006, 135 (02) :165-173

[3]

Bloomfield CD, 1998, CANCER RES, V58, P4173

[4] The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: Results of the UK MRC AML 10 trial [J].

Burnett, AK ;

Wheatley, K ;

Goldstone, AH ;

Stevens, RF ;

Hann, IM ;

Rees, JHK ;

Harrison, G .

BRITISH JOURNAL OF HAEMATOLOGY, 2002, 118 (02) :385-400

[5] Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22):: Results from CALGB 8461 [J].

Byrd, JC ;

Ruppert, AS ;

Mrózek, K ;

Carroll, AJ ;

Edwards, CG ;

Arthur, DC ;

Pettenatti, MJ ;

Stamberg, J ;

Koduru, PRK ;

Moore, JO ;

Mayer, RJ ;

Davey, FR ;

Larson, RA ;

Bloomfield, CD .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) :1087-1094

[6] Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia:: Rare events related to DNA-topoisomerase II inhibitors? [J].

Dissing, M ;

Le Beau, MM ;

Pedersen-Bjergaard, J .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (05) :1890-1896

[7]

ERICKSON P, 1992, BLOOD, V80, P1825

[8] Secondary leukemias induced by topoisomerase-targeted drugs [J].

Felix, CA .

BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1998, 1400 (1-3) :233-255

[9] Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias [J].

Krauter, J ;

Görlich, K ;

Ottmann, O ;

Lübbert, M ;

Döhner, H ;

Heit, W ;

Kanz, L ;

Ganser, A ;

Heil, G .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (23) :4413-4422

[10] A ≥ 1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse [J].

Lane, Steven ;

Saal, Russell ;

Mollee, Peter ;

Jones, Mark ;

Grigg, Andrew ;

Taylor, Kerry ;

Seymour, John ;

Kennedy, Glen ;

Williams, Bronwyn ;

Grimmett, Karen ;

Griffiths, Vanessa ;

Gill, Devinder ;

Hourigan, Matthew ;

Marlton, Paula .

LEUKEMIA & LYMPHOMA, 2008, 49 (03) :517-523

← 1 2 →